Sam Brusco, Associate Editor02.22.22
Gramercy Extremity Orthopedics (GEO) has earned U.S. Food and Drug Administration (FDA) clearance for its for its distal fibular ankle fracture plating and multi-application extremity plating systems.
“These new plates were designed to seamlessly integrate into our current system, utilizing the same single-use sterile instrument kits and screws that we bring to market via the GEO Cart,” GEO chief technology officer Paul Vasta told the press. “The release of these new plating systems represents the continued expansion of GEO’s product line and highlights the unique benefits of the GEO Cart. Having a well-rounded product offering for foot and ankle procedures, sterile packaged and always ready in the OR, is extremely advantageous to surgeons, the facilities, and most importantly, their patients.”
“Orthopedics, and by default healthcare in the United States, is at an inflection point. We are excited to offer leadership in our space, which is now being driven by the demand for traceable and efficient instrument and implant delivery models,” added Michael Simpson, GEO’s CEO. “In expanding our product offering with these two new lines, we are better positioned to partner with our IDNs, health systems, and surgery centers. GEO will continue to redefine what we believe is the future of sustainable patient care and to support our surgeons in their essential work.”
“These new plates were designed to seamlessly integrate into our current system, utilizing the same single-use sterile instrument kits and screws that we bring to market via the GEO Cart,” GEO chief technology officer Paul Vasta told the press. “The release of these new plating systems represents the continued expansion of GEO’s product line and highlights the unique benefits of the GEO Cart. Having a well-rounded product offering for foot and ankle procedures, sterile packaged and always ready in the OR, is extremely advantageous to surgeons, the facilities, and most importantly, their patients.”
“Orthopedics, and by default healthcare in the United States, is at an inflection point. We are excited to offer leadership in our space, which is now being driven by the demand for traceable and efficient instrument and implant delivery models,” added Michael Simpson, GEO’s CEO. “In expanding our product offering with these two new lines, we are better positioned to partner with our IDNs, health systems, and surgery centers. GEO will continue to redefine what we believe is the future of sustainable patient care and to support our surgeons in their essential work.”